Mustang Bio, Inc. (MBIO): Price and Financial Metrics


Mustang Bio, Inc. (MBIO): $0.69

0.03 (+4.40%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add MBIO to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

MBIO Stock Price Chart Interactive Chart >

Price chart for MBIO

MBIO Price/Volume Stats

Current price $0.69 52-week high $4.06
Prev. close $0.66 52-week low $0.61
Day low $0.65 Volume 643,600
Day high $0.69 Avg. volume 909,663
50-day MA $0.84 Dividend yield N/A
200-day MA $1.67 Market Cap 69.27M

Mustang Bio, Inc. (MBIO) Company Bio


Mustang Bio Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel cancer immunotherapy products based on the chimeric antigen receptor engineered T cell technology. Its lead programs include MB-101 for the treatment of brain cancer that is in Phase I trials; and MB-102, a therapeutic agent in acute myeloid leukemia, which is in Phase I trials. The company was founded in 2015 and is based in New York, New York. Mustang Bio Inc. is a subsidiary of Fortress Biotech, Inc.


MBIO Latest News Stream


Event/Time News Detail
Loading, please wait...

MBIO Latest Social Stream


Loading social stream, please wait...

View Full MBIO Social Stream

Latest MBIO News From Around the Web

Below are the latest news stories about Mustang Bio Inc that investors may wish to consider to help them evaluate MBIO as an investment opportunity.

Mustang Bio Announces City of Hope MB-105 Prostate Stem Cell Antigen CAR T Data Selected for Presentation at the 2022 American Society of Clinical Oncology Genitourinary Cancers Symposium

WORCESTER, Mass., Feb. 15, 2022 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors and rare genetic diseases, today announced that City of Hope Phase 1 clinical trial data on MB-105, a prostate stem cell antigen (“PSCA”) chimeric antigen receptor (“CAR”) T-cell therapy administered systemically to pati

Yahoo | February 15, 2022

Mustang Bio Selected as a Bronze Winner in Eighteenth Annual Team Massachusetts Economic Impact Awards

WORCESTER, Mass., Feb. 08, 2022 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors and rare genetic diseases, today announced the company was selected as the Bronze winner for the Central region in the Eighteenth Annual Team Massachusetts Economic Impact Awards presented by MassEcon. The awards honor c

Yahoo | February 8, 2022

One Mustang Bio, Inc. (NASDAQ:MBIO) insider upped their stake by 25% in the previous year

Viewing insider transactions for Mustang Bio, Inc.'s ( NASDAQ:MBIO ) over the last year, we see that insiders were net...

Yahoo | February 7, 2022

FDA Holds Mustang Bio's Gene Therapy IND For Compromised Immune System Disorder

The FDA has issued a hold, pending Chemistry, Manufacturing & Controls (CMC) clearance, on Mustang Bio Inc's (NASDAQ: MBIO) Investigational New Drug (IND) application for MB-207 in patients with X-linked severe combined immunodeficiency (XSCID). The application was submitted to initiate a pivotal Phase 2 study to assess MB-207 (lentiviral gene therapy) in patients who have been previously treated with a hematopoietic stem cell transplantation, and for whom re-treatment is indicated. The FDA has

Yahoo | January 25, 2022

Mustang Bio Provides an Update on its IND Application for MB-207, a Lentiviral Gene Therapy for Treatment of X-linked Severe Combined Immunodeficiency (“XSCID”) in Previously Transplanted Patients

WORCESTER, Mass., Jan. 24, 2022 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors and rare genetic diseases, today announced that the U.S. Food and Drug Administration (“FDA”) has issued a hold, pending Chemistry, Manufacturing and Controls (“CMC”) clearance, on the Company’s Investigational New Drug

Yahoo | January 24, 2022

Read More 'MBIO' Stories Here

MBIO Price Returns

1-mo -9.40%
3-mo -23.21%
6-mo -65.50%
1-year -79.40%
3-year -80.29%
5-year N/A
YTD -58.43%
2021 -56.14%
2020 -7.23%
2019 38.78%
2018 -75.48%
2017 N/A

Continue Researching MBIO

Want to see what other sources are saying about Mustang Bio Inc's financials and stock price? Try the links below:

Mustang Bio Inc (MBIO) Stock Price | Nasdaq
Mustang Bio Inc (MBIO) Stock Quote, History and News - Yahoo Finance
Mustang Bio Inc (MBIO) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.4697 seconds.